{"organizations": [], "uuid": "87890c74317b43adb9fd0c927b0a731fffc017ea", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/us-mylan-nl-results/mylan-fourth-quarter-earnings-fall-with-epipen-sales-weak-generic-prices-idUSKCN1GC378", "country": "US", "domain_rank": 408, "title": "UPDATE 1-Mylan Q4 earnings fall with EpiPen sales, weak generic prices", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-01T00:21:00.000+02:00", "replies_count": 0, "uuid": "87890c74317b43adb9fd0c927b0a731fffc017ea"}, "author": "", "url": "https://www.reuters.com/article/us-mylan-nl-results/mylan-fourth-quarter-earnings-fall-with-epipen-sales-weak-generic-prices-idUSKCN1GC378", "ord_in_thread": 0, "title": "UPDATE 1-Mylan Q4 earnings fall with EpiPen sales, weak generic prices", "locations": [], "entities": {"persons": [{"name": "tom brown", "sentiment": "none"}, {"name": "michael erman", "sentiment": "none"}, {"name": "chris reese", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "new york", "sentiment": "none"}], "organizations": [{"name": "mylan", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "mylan nv", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK (Reuters) - Mylan NV ( MYL.O ) said on Wednesday its fourth-quarter earnings fell due to declining revenue from its EpiPen emergency allergy injector and weak U.S. prices for generic drugs.\nThe drugmaker reported net income of $244.3 million, or 46 cents a share, in the quarter, down from $417.5 million, or 78 cents a share, last year.\nExcluding one-time items, the company said it earned $1.43 a share. Analysts on average were expecting $1.41, according to Thomson Reuters I/B/E/S.\nRevenue in the quarter fell 1 percent to $3.24 billion, coming in below the average analyst expectation of $3.3 billion.\nMylan forecast adjusted earnings per share in the range of $5.20 to $5.60 for 2018, in line with analyst estimates.\nReporting by Michael Erman; Editing by Chris Reese and Tom Brown\n ", "external_links": [], "published": "2018-03-01T00:21:00.000+02:00", "crawled": "2018-03-01T00:34:55.021+02:00", "highlightTitle": ""}